【港股异动 | 创新药概念多数走强政策支持创新药全链条发展机构称创新药仍为重要投资主线之一】智通财经APP获悉，创新

智通财经2025-07-03

【港股异动 | 创新药概念多数走强政策支持创新药全链条发展机构称创新药仍为重要投资主线之一】智通财经APP获悉，创新药概念早盘多数走强，截至发稿，康方生物(09926.HK)涨11.31%，报103.3港元；亚盛医药-B(06855.HK)涨9.15%，报85.25港元；科伦博泰生物-B(06990.HK)涨7.48%，报353.6港元；信达生物(01801.HK)涨6.56%，报84.5港元...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2548554825?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-03 11:26","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2548554825","market":"us","top_or_hot":-1,"title":"【港股异动 | 创新药概念多数走强 政策支持创新药全链条发展 机构称创新药仍为重要投资主线之一】智通财经APP获悉，创新","media":"智通财经","content":"<div>\n<p>【港股异动 | 创新药概念多数走强 政策支持创新药全链条发展 机构称创新药仍为重要投资主线之一】智通财经APP获悉，创新药概念早盘多数走强，截至发稿，康方生物(09926.HK)涨11.31%，报103.3港元；亚盛医药-B(06855.HK)涨9.15%，报85.25港元；科伦博泰生物-B(06990.HK)涨7.48%，报353.6港元；信达生物(01801.HK)涨6.56%，报84.5港元...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=ganggu\">网页链接</a>\n\n</div>\n","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【港股异动 | 创新药概念多数走强 政策支持创新药全链条发展 机构称创新药仍为重要投资主线之一】智通财经APP获悉，创新</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【港股异动 | 创新药概念多数走强 政策支持创新药全链条发展 机构称创新药仍为重要投资主线之一】智通财经APP获悉，创新\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-03 11:26 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.zhitongcaijing.com/immediately.html?type=ganggu><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【港股异动 | 创新药概念多数走强 政策支持创新药全链条发展 机构称创新药仍为重要投资主线之一】智通财经APP获悉，创新药概念早盘多数走强，截至发稿，康方生物(09926.HK)涨11.31%，报103.3港元；亚盛医药-B(06855.HK)涨9.15%，报85.25港元；科伦博泰生物-B(06990.HK)涨7.48%，报353.6港元；信达生物(01801.HK)涨6.56%，报84.5港元...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=ganggu\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0417516571.SGD","symbol_name":"Allianz Oriental Income Cl AT Acc SGD","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","article_id":"2548554825","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2548554825","pubTimestamp":1751513186,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【港股异动 | 创新药概念多数走强 政策支持创新药全链条发展 机构称创新药仍为重要投资主线之一】智通财经APP获悉，创新药概念早盘多数走强，截至发稿，康方生物(09926.HK)涨11.31%，报10","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","BK1588":"回港中概股","BK1161":"生物科技","06855":"亚盛医药-B","BK4531":"中概回港概念","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","BK4588":"碎股","LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","06978":"永泰生物-B","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK1574":"生物医药B类股","AAPG":"亚盛医药","LU1720050803.USD":"安联全方位中国股票基金","BK1583":"高瓴概念","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","BK4526":"热门中概股","BK4139":"生物科技","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0348783233.USD":"安联东方收入型 CI A Dis美元","09926":"康方生物","BK4585":"ETF&股票定投概念","01801":"信达生物","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","BK4548":"巴美列捷福持仓","09688":"再鼎医药","BK1589":"北水核心资产","06990":"科伦博泰生物-B","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","ZLAB":"再鼎医药"},"translate_title":"[Hong Kong stocks have changed the concept of innovative drugs, and most of them have strengthened. Policies support the development of the entire chain of innovative drugs. Institutions say that innovative drugs are still one of the important investment lines] Zhitong Finance APP learned that innovation","themeId":"1888ce0878b381abf8dca3aec6acfa38","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"06990":1,"AAPG":1,"ZLAB":1,"06978":1,"01801":1,"09926":1,"06855":1,"09688":1},"content_text":"【港股异动 | 创新药概念多数走强 政策支持创新药全链条发展 机构称创新药仍为重要投资主线之一】智通财经APP获悉，创新药概念早盘多数走强，截至发稿，康方生物(09926.HK)涨11.31%，报103.3港元；亚盛医药-B(06855.HK)涨9.15%，报85.25港元；科伦博泰生物-B(06990.HK)涨7.48%，报353.6港元；信达生物(01801.HK)涨6.56%，报84.5港元；再鼎医药(09688.HK)涨5.92%，报29.5港元。","kind":"live","is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2548554825","isCrawlerRequest":true}

【港股异动 | 创新药概念多数走强 政策支持创新药全链条发展 机构称创新药仍为重要投资主线之一】智通财经APP获悉，创新

精彩评论

【港股异动 | 创新药概念多数走强政策支持创新药全链条发展机构称创新药仍为重要投资主线之一】智通财经APP获悉，创新